Suppr超能文献

抑制热休克因子1可抑制肝癌细胞系的生长以及小鼠中AKT驱动的肝癌发生。

Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines and AKT-driven hepatocarcinogenesis in mice.

作者信息

Cigliano Antonio, Wang Chunmei, Pilo Maria G, Szydlowska Marta, Brozzetti Stefania, Latte Gavinella, Pes Giovanni M, Pascale Rosa M, Seddaiu Maria A, Vidili Gianpaolo, Ribback Silvia, Dombrowski Frank, Evert Matthias, Chen Xin, Calvisi Diego F

机构信息

Institut für Pathologie, Universitätsmedizin Greifswald, Greifswald, Germany.

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, USA.

出版信息

Oncotarget. 2017 Apr 7;8(33):54149-54159. doi: 10.18632/oncotarget.16927. eCollection 2017 Aug 15.

Abstract

Upregulation of the heat shock transcription factor 1 (HSF1) has been described as a frequent event in many cancer types, but its oncogenic role in hepatocellular carcinoma (HCC) remains poorly delineated. In the present study, we assessed the function(s) of HSF1 in hepatocarcinogenesis via and approaches. In particular, we determined the importance of HSF1 on v-Akt murine thymoma viral oncogene homolog (AKT)-induced liver cancer development in mice. We found that knockdown of HSF1 activity via specific siRNA triggered growth restraint by suppressing cell proliferation and inducing massive cell apoptosis in human HCC cell lines. At the molecular level, HSF1 inhibition was accompanied by downregulation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) cascade and related metabolic pathways. Most importantly, overexpression of a dominant negative form of HSF1 (HSF1dn) in the mouse liver via hydrodynamic gene delivery led to the inhibition of mouse hepatocarcinogenesis driven by overexpression of AKT. In human liver cancer specimens, we detected that HSF1 is progressively induced from human non-tumorous surrounding livers to HCC, reaching the highest expression in the tumors characterized by the poorest outcome (as defined by the length of patients' survival). In conclusion, HSF1 is an independent prognostic factor in liver cancer and might represent an innovative therapeutic target in HCC subsets characterized by activation of the AKT/mTOR pathway.

摘要

热休克转录因子1(HSF1)的上调在许多癌症类型中被描述为常见事件,但其在肝细胞癌(HCC)中的致癌作用仍不清楚。在本研究中,我们通过 和 方法评估了HSF1在肝癌发生中的功能。特别是,我们确定了HSF1对v-Akt小鼠胸腺瘤病毒癌基因同源物(AKT)诱导的小鼠肝癌发生发展的重要性。我们发现,通过特异性siRNA敲低HSF1活性可通过抑制细胞增殖和诱导人肝癌细胞系中的大量细胞凋亡来触发生长抑制。在分子水平上,HSF1抑制伴随着磷酸肌醇3激酶(PI3K)/AKT/雷帕霉素哺乳动物靶标(mTOR)级联反应和相关代谢途径的下调。最重要的是,通过流体动力学基因传递在小鼠肝脏中过表达显性负性形式的HSF1(HSF1dn)导致由AKT过表达驱动的小鼠肝癌发生受到抑制。在人类肝癌标本中,我们检测到HSF1从人类非肿瘤周围肝脏到HCC逐渐被诱导,在以最差预后(由患者生存时间定义)为特征的肿瘤中表达最高。总之,HSF1是肝癌的独立预后因素,可能代表了以AKT/mTOR途径激活为特征的HCC亚组中的一个创新治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4f3/5589569/c1a07946b105/oncotarget-08-54149-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验